{
    "clinical_study": {
        "@rank": "50375", 
        "acronym": "SHPS", 
        "arm_group": [
            {
                "arm_group_label": "Sorafenib", 
                "arm_group_type": "Experimental", 
                "description": "400 mg (2 capsules) taken by mouth once a day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 capsules taken by mouth once a day"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this clinical trial is to determine the safety and effects of the study\n      drug, sorafenib, in adults diagnosed with hepatopulmonary syndrome (HPS). The study will\n      evaluate how well the drug is tolerated and its effect on the level of oxygen in the blood\n      and the function of the lung vessels."
        }, 
        "brief_title": "Sorafenib for Hepatopulmonary Syndrome", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatopulmonary Syndrome", 
        "condition_browse": {
            "mesh_term": "Hepatopulmonary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of HPS:\n\n               1. AaPO2 \u2265 15 mm Hg (\u2265 20 mm Hg for age > 64 yrs)\n\n               2. Intrapulmonary shunting\n\n               3. Absence of significant restriction (TLC < 70%) or obstruction (FEV1 < 80% &\n                  FEV1/FVC < 70%)\n\n               4. Presence of cirrhosis and/or portal hypertension\n\n          -  Child-Pugh class A or B liver disease\n\n          -  Platelet count \u2265 60 \u00d710e9 per liter\n\n          -  Hemoglobin \u2265 8.5 g per deciliter\n\n          -  International normalized ratio \u2264 2.3\n\n          -  Albumin \u2265 2.8 g per deciliter\n\n          -  Total bilirubin \u2264 3 mg per deciliter\n\n          -  Alanine aminotransferase and aspartate aminotransferase \u2264 5 times the upper limit of\n             the normal range\n\n          -  Serum creatinine \u2264 1.5 times the upper limit of the normal range and not receiving\n             dialysis\n\n          -  Negative pregnancy test (for women of childbearing potential) at both screening and\n             baseline visits. Post-menopausal women (defined as no menses for one year) and\n             surgically sterilized women are not required to undergo a pregnancy test.\n\n          -  Subjects (men and women) of childbearing potential must agree to use medically\n             acceptable contraception beginning at the signing of the Informed Consent Form until\n             at least 14 days after the last dose of study drug.\n\n          -  Age \u2265 21 years\n\n          -  Ability to provide informed consent\n\n        Exclusion Criteria:\n\n          -  Recent chronic heavy alcohol consumption\n\n          -  Enrollment in a clinical trial or concurrent use of another investigational drug or\n             device therapy (i.e., outside of study treatment) during, or within 28 days of\n             screening visit\n\n          -  Current hepatic encephalopathy\n\n          -  Active infection\n\n          -  Diagnosis of portopulmonary hypertension\n\n          -  WHO Class IV functional status\n\n          -  Congenital long-QT syndrome\n\n          -  Subjects who have used strong CYP3A4 inducers (e.g., phenytoin, carbamazepine,\n             phenobarbital, St. John's Wort [Hypericum perforatum], dexamethasone at a dose of\n             greater than 16 mg daily, or rifampin [rifampicin], and/or rifabutin) within 28 days\n             before randomization\n\n          -  Subjects who are currently taking Coumadin\u00ae(warfarin)\n\n          -  Active or clinically significant cardiac disease, including:\n\n               1. Active coronary artery disease\n\n               2. Unstable angina (anginal symptoms at rest), new-onset angina within 12 weeks\n                  before randomization, or myocardial infarction within 24 weeks before\n                  randomization\n\n          -  Liver or other solid organ transplant recipients\n\n          -  Expectation of liver transplant within four months of randomization\n\n          -  Hepatocellular carcinoma\n\n          -  Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm\n             Hg on repeated measurement) despite optimal medical management.\n\n          -  Any hemorrhage/bleeding event of NCI-Common Toxicity Criteria for Adverse Effects\n             v4.0 Grade 3 or higher within 4 weeks before randomization\n\n          -  Presence of a non-healing wound, non-healing ulcer, or bone fracture\n\n          -  Women who are pregnant or breast-feeding\n\n          -  Major surgery 28 days prior to randomization\n\n          -  Subjects with any previously untreated or concurrent cancer except cervical cancer\n             in-situ, treated basal cell carcinoma, or superficial bladder tumor.  Subjects\n             surviving a cancer that was curatively treated and without evidence of disease for\n             more than 3 years before randomization are allowed. All cancer treatments\n             (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor\n             embolization) must be completed at least 3 years prior to study entry (i.e.,\n             signature date of the informed consent form).\n\n          -  Inability to comply with the protocol and/or not willing or not available for\n             follow-up assessments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02021929", 
            "org_study_id": "819185"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sorafenib", 
                "intervention_name": "Sorafenib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Randomized Controlled Trial", 
            "Clinical Trial", 
            "sorafenib", 
            "Hepatopulmonary Syndrome"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "stadheim.linda@mayo.edu", 
                    "last_name": "Linda Stadheim, RN", 
                    "phone": "507-284-0141"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Michael Krowka, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sm3417@cumc.columbia.edu", 
                    "last_name": "Samina Munir", 
                    "phone": "212-305-3839"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University-NewYork-Presbyterian Hospital"
                }, 
                "investigator": {
                    "last_name": "Robert Brown, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sharkosk@exchange.upenn.edu", 
                    "last_name": "Tiffany Sharkoski, 15", 
                    "phone": "215-746-4186"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania - Perelman Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Steven M Kawut, MD, MS", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "David Goldberg, MD, MSCE", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Lacie.L.Ford@uth.tmc.edu", 
                    "last_name": "Lacie Ford"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "University of Texas Health Science Center at Houston Medical School"
                }, 
                "investigator": {
                    "last_name": "Michael B Fallon, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial", 
        "overall_contact": {
            "email": "sharkosk@exchange.upenn.edu", 
            "last_name": "Tiffany Sharkoski", 
            "phone": "215-746-4186"
        }, 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Steven M Kawut, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Data and Safety Monitoring Board", 
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Difference in changes in  alveolar-arterial oxygen gradient between sorafenib and placebo groups", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02021929"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Difference in changes in intrapulmonary shunting between sorafenib and placebo groups", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Difference in changes in hematopoietic progenitor cells and other biomarker levels between sorafenib and placebo groups", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "Difference in changes in hematopoietic progenitor cells and other biomarker levels between sorafenib and placebo groups", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}